Ys Lu - Institute of High Energy Physics, Chinese Academy of Sciences

基本信息

浏览量：0

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 314 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

LBA2 Datopotamab Deruxtecan (Dato-Dxd) Vs Chemotherapy (CT) in Pretreated, Inoperable/metastatic HR+/HER2– Breast Cancer (BC): Additional Safety Analysis from TROPION-Breast01

K. Jhaveri,A. Bardia, S-A. Im,S. Pernas Simon,M. De Laurentiis, S. Wang, N. Martinez, G. Santos Borges,D.W. Cescon, M. Hattori,Y-S. Lu,E.P. Hamilton,

ESMO Open (2024)

引用0浏览0引用

Using Graph Neural Networks to Reconstruct Charged Pion Showers in the CMS High Granularity Calorimeter

M. Aamir,B. Acar,G. Adamov, T. Adams,C. Adloff,S. Afanasiev, C. Agrawal,A. Ahmad, H. A. Ahmed, S. Akbar,N. Akchurin, B. Akgul,

arxiv（2024）

引用0浏览0引用

Quality of life (QOL) analysis from the phase II RIGHT choice study of first-line ribociclib (RIB) plus endocrine therapy (ET) vs combination chemotherapy (combo CT) in aggressive HR+/HER2-advanced breast cancer (ABC)

Y. Eralp,H. Abdel-Razeq, S-A. Im,J. Rihani,Y-S. Lu,Y. S. Yap,H. A. Azim,N. Prasongsook,L. Zhukova,H. Hu,T. Delgar Alfaro, J. Wu,

ANNALS OF ONCOLOGY (2023): S372-S373

引用0浏览0引用

57MO First-line (1L) Ribociclib (RIB) + Endocrine Therapy (ET) Vs Combination Chemotherapy (combo CT) in HR+/HER2− Advanced Breast Cancer (ABC): A Post Hoc Analysis of Asian and Non-Asian Patients (pts) from the Phase II RIGHT Choice Trial

Y-S. Yap, S-A. Im,Y-S. Lu,H.A. Azim,Y. Eralp,G.B. Kanakasetty,H. Abdel-Razeq,L. Zhukova,A. Thuerigen,T. Delgar Alfaro, J. Wu,M. Gao,

Annals of oncology（2023）

引用0浏览0引用

LBA11 Datopotamab Deruxtecan (Dato-Dxd) Vs Chemotherapy in Previously-Treated Inoperable or Metastatic Hormone Receptor-Positive, HER2-negative (HR+/HER2–) Breast Cancer (BC): Primary Results from the Randomised Phase III TROPION-Breast01 Trial

A. Bardia,K. Jhaveri, S-A. Im,S. Pernas Simon,M. De Laurentiis, S. Wang, N. Martinez, G. Santos Borges,D.W. Cescon, M. Hattori,Y-S. Lu,E.P. Hamilton,

Annals of Oncology (2023): S1264-S1265

引用0浏览0引用

Temporal Structures in Electron Spectra and Charge Sign Effects in Galactic Cosmic Rays

M. Aguilar,L. Ali Cavasonza,G. Ambrosi,L. Arruda,N. Attig, C. Bagwell,F. Barao,L. Barrin,A. Bartoloni,S. Basegmez-du Pree,R. Battiston,M. Behlmann,

Physical review letters（2023）

引用4浏览0WOS引用

[Clinical Analysis of 11 Cases of High-Grade B-cell Lymphoma in Children]

J Liu,J Wang,J Zhu, Y Zhang,S Y Lu, F,J T Huang, Y P Wu,F Y Cai, R Q Cai, Z,X F Sun,

PubMedno. 2 (2023): 151-153

引用0浏览0WOS引用

Capivasertib (C) plus fulvestrant (F) for patients (pts) with aromatase inhibitor (AI)-resistant HR+/HER2e advanced breast cancer (ABC): Phase III CAPItello-291 trial Chinese cohort

X. Hu,Q. Zhang, T. Sun,H. Xiong, W. Li,Y. Teng,Y-S. Lu,L-M. Tseng, M. Yan, H. Li, D. Pang,S. C. Chen,

ANNALS OF ONCOLOGY (2023): S1485-S1486

引用0浏览0引用

1220P Comprehensive Diagnose of Programmed Death-Ligand 1 from Two-Dimensional to Three-Dimensional in Breast Cancer with Computer-Aided Artificial Intelligence System

Y-H. Lee,Y-C. Lin, Y-H. Hsieh,C-H. Yang, Y-A. Chen,C-H. Lin,M-Y. Wang,W-H. Kuo, Y-Y. Lin,Y-S. Lu

Annals of Oncology（2023）

引用0浏览0引用

LBA5 Capivasertib (C) + Fulvestrant (F) for Patients (pts) with Aromatase Inhibitor (Ai)-Resistant HR+/HER2– Advanced Breast Cancer (ABC): Phase III CAPItello-291 Trial Chinese Cohort

X. Hu,Q. Zhang, T. Sun,H. Xiong, W. Li,Y. Teng,Y-S. Lu,L-M. Tseng, M. Yan, H. Li, D. Pang,S.C. Chen,

Annals of Oncology（2023）

引用0浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn